CSL maintains momentum in drive to be 'global biotech leader'

Australia’s CSL Limited (ASX: CSL) has sought to shed light on the promise of its pipeline at its annual R&D investor briefing.

The Melbourne-based firm, which calls itself a global biotech leader, invested approximately $1.16 billion in R&D last year and now has a market capitalization value in excess of $134 billion, is comprised of three businesses, CSL Behring, CSL Seqirus and CSL Vifor.

CSL is focused on the areas of immunology, hematology, respiratory, cardiovascular and metabolic, transplant, nephrology and vaccines, using its strategic scientific platforms of plasma protein technology, recombinant technology, cell and gene therapy, and sa-mRNA, adjuvanted, cell-based and egg-based vaccines.